The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study

被引:451
作者
Burslem, George M. [1 ]
Smith, Blake E. [1 ]
Lai, Ashton C. [1 ]
Jaime-Figueroa, Saul [1 ]
McQuaid, Daniel C. [1 ]
Bondeson, Daniel P. [1 ]
Toure, Momar [1 ]
Dong, Hanqing [2 ]
Qian, Yimin [2 ]
Wang, Jing [2 ]
Crew, Andrew P. [2 ]
Hines, John [1 ]
Crews, Craig M. [1 ,3 ,4 ]
机构
[1] Yale Univ, Dept Mol Cellular & Dev Biol, 219 Prospect St, New Haven, CT 06520 USA
[2] Arvinas LLC, 5 Sci Pk, New Haven, CT USA
[3] Yale Univ, Dept Chem, New Haven, CT 06520 USA
[4] Yale Univ, Dept Pharmacol, New Haven, CT 06520 USA
关键词
GROWTH-FACTOR RECEPTOR; KINASE INHIBITOR; BREAST-CANCER; C-MET; TYROSINE KINASES; LUNG-CANCER; HSP90; UBIQUITINATION; RESISTANCE; TIVANTINIB;
D O I
10.1016/j.chembiol.2017.09.009
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Proteolysis targeting chimera (PROTAC) technology has emerged over the last two decades as a powerful tool for targeted degradation of endogenous proteins. Herein we describe the development of PROTACs for receptor tyrosine kinases, a protein family yet to be targeted for induced protein degradation. The use of VHL-recruiting PROTACs against this protein family reveals several advantages of degradation over inhibition alone: direct comparisons of fully functional, target-degrading PROTACs with target-inhibiting variants that contain an inactivated E3 ligase-recruiting ligand show that degradation leads to more potent inhibition of cell proliferation and a more durable and sustained downstream signaling response, and thus addresses the kinome rewiring challenge seen with many receptor tyrosine kinase inhibitors. Combined, these findings demonstrate the ability to target receptor tyrosine kinases for degradation using the PROTAC technology and outline the advantages of this degradation-based approach.
引用
收藏
页码:67 / +
页数:14
相关论文
共 64 条
  • [41] The Plasticity of Oncogene Addiction: Implications for Targeted Therapies Directed to Receptor Tyrosine Kinases
    Pillay, Vinochani
    Allaf, Layal
    Wilding, Alex L.
    Donoghue, Jacqui F.
    Court, Naomi W.
    Greenall, Steve
    Scott, Andrew M.
    Johns, Terrance G.
    [J]. NEOPLASIA, 2009, 11 (05): : 448 - U46
  • [42] A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response
    Pratz, Keith W.
    Cortes, Jorge
    Roboz, Gail J.
    Rao, Niranjan
    Arowojolu, Omotayo
    Stine, Adam
    Shiotsu, Yukimasa
    Shudo, Aiko
    Akinaga, Shiro
    Small, Donald
    Karp, Judith E.
    Levis, Mark
    [J]. BLOOD, 2009, 113 (17) : 3938 - 3946
  • [43] PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
    Raina, Kanak
    Lu, Jing
    Qian, Yimin
    Altieri, Martha
    Gordon, Deborah
    Rossi, Ann Marie K.
    Wang, Jing
    Chen, Xin
    Dong, Hanqing
    Siu, Kam
    Winkler, James D.
    Crew, Andrew P.
    Crews, Craig M.
    Coleman, Kevin G.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2016, 113 (26) : 7124 - 7129
  • [44] Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation
    Sakamoto, KM
    Kim, KB
    Kumagai, A
    Mercurio, F
    Crews, CM
    Deshaies, RJ
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (15) : 8554 - 8559
  • [45] Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer
    Scagliotti, Giorgio
    von Pawel, Joachim
    Novello, Silvia
    Ramlau, Rodryg
    Favaretto, Adolfo
    Barlesi, Fabrice
    Akerley, Wallace
    Orlov, Sergey
    Santoro, Armando
    Spigel, David
    Hirsh, Vera
    Shepherd, Frances A.
    Sequist, Lecia V.
    Sandler, Alan
    Ross, Jeffrey S.
    Wang, Qiang
    von Roemeling, Reinhard
    Shuster, Dale
    Schwartz, Brian
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (24) : 2667 - +
  • [46] Schiedel M., 2017, J MED CHEM
  • [47] Cell Signaling by Receptor Tyrosine Kinases
    Lemmon, Mark A.
    Schlessinger, Joseph
    [J]. CELL, 2010, 141 (07) : 1117 - 1134
  • [48] Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics
    Schneekloth, Ashley R.
    Pucheault, Mathieu
    Tae, Hyun Seop
    Crews, Craig M.
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (22) : 5904 - 5908
  • [49] Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non-Small-Cell Lung Cancer
    Sequist, Lecia V.
    von Pawel, Joachim
    Garmey, Edward G.
    Akerley, Wallace L.
    Brugger, Wolfram
    Ferrari, Dora
    Chen, Yinpu
    Costa, Daniel B.
    Gerber, David E.
    Orlov, Sergey
    Ramlau, Rodryg
    Arthur, Susan
    Gorbachevsky, Igor
    Schwartz, Brian
    Schiller, Joan H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (24) : 3307 - 3315
  • [50] Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker
    Solca, Flavio
    Dahl, Goeran
    Zoephel, Andreas
    Bader, Gerd
    Sanderson, Michael
    Klein, Christian
    Kraemer, Oliver
    Himmelsbach, Frank
    Haaksma, Eric
    Adolf, Guenther R.
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2012, 343 (02) : 342 - 350